Novartis Q4 Results
Entresto
Content
Click below to navigate
through the document
EntrestoⓇ delivers 31% FY growth with sales reaching USD 6bn.
Expecting USD 7bn peak sales
GROWTH
↓
↑
Company overview
Financial review
Conclusions
Appendix
References
Sales evolution
USD m, % cc
US
Ex-US
1,291
US weekly TRX1
Continues strong momentum in Q4
Total prescriptions (000)
FY USD 6.0bn
+31%
.
US: +27% CC
120
.
Ex-US: +26% CC
~1.4m TRx
110
in Q41
+26%
·
100
China/Japan: Contribution from HTN2
1,635
90
080
80
Confidence in future growth
70
755
597
660
60
50
40
40
30
880
694
20
10
0
Q4 2022
Q4 2023
July 2015
Dec 2023
.
·
Strong guidelines position³ (US/EU)
Further penetration in HF and HTN
US: Forecasting purposes, we
assume EntrestoⓇ LoE in 2025
EU: RDP to Nov 20264
See last page for references (footnotes 1-4).
HTN hypertension.
-
LOE loss of exclusivity.
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report.
RDP - Regulatory data protection.
□ NOVARTIS | Reimagining Medicine.
TRX total prescriptions. HF - heart failure.
Novartis Q4 Results | January 31, 2024
7View entire presentation